Cancer Clinical Trials | Norton Healthcare Louisville, Ky.

Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Current Norton Cancer Institute clinical trials include:

Acute Myeloid Leukemia (AML)

Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (? 60 […]

Acute Myeloid Leukemia (AML)

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage

Acute Myeloid Leukemia (AML)

A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)

Advanced Solid Tumors

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects with Advanced Solid Tumors

Advanced Solid Tumors

A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies

Advanced Solid Tumors

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors – ARTISTRY-1

Biliary Tract Cancer

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

Bladder Cancer

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Brain Tumor

Southeastern Study of Cancer and the Environment

Brain Tumor

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Breast Cancer

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axilla

Breast Cancer

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Breast Cancer

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Breast Cancer

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast […]

Breast Cancer

Elacestrant Monotherapy Vs. Standard Of Care For The Treatment Of Patients With Er+/Her2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial (EMERALD)

Breast Cancer

A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced

Breast Cancer

A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (New Adjuvant TriAl with Ri

Breast Cancer

Randomized, Non-comparative Neoadjuvant Phase II Study in Postmenopausal Women with ER+/HER2- Breast Cancer >/=2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8)

Cancer

AANS and ASTRO Stereotactic Radiosurgery Registry (SRS Registry)

Cancer

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an anti-PD-1 antibody, for Subjects with HER2-expressing Advanced Breast

Chronic Lymphocytic Leukemia (CLL)

A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Chronic Lymphocytic Leukemia (CLL)

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previo

Chronic Lymphocytic Leukemia (CLL)

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical Hodgkin Lymphoma (cHL)

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

Classical Hodgkin Lymphoma (cHL)

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Colorectal Cancer

A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Cutaneous Squamous Cell Carcinoma (cSCC)

A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma

Diffuse Large B-cell Lymphoma (DLBCL)

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL

Education

Effects of a Smartphone App on Compliance and Function in Patients with Breast Cancer

Follicular Lymphoma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Ly

Follicular Lymphoma

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Gastroesophageal Cancer

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Me

Gastrointestinal Stromal Tumor (GIST)

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Gene-modified T cells (GM T cells)

Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Glioma

NCCTG N0577/Endorsed Study: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Head & Neck Squamous Cell Carcinoma (HNSCC)

NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin

Hepatocellular Carcinoma (HCC)

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma

Hodgkin Lymphoma

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology

Hodgkin Lymphoma

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Leukemia

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients ?18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit for Standard Induction Chemotherapy

Leukemia

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

Limited Stage Small Cell Lung Cancer (LS-SCLC)

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Lung Cancer

A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with all Stages of Lung Cancer

Lung Cancer/ Breast Cancer

A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for advanced non-small cell lung cancer and metastatic tripl

Lymphoma

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Lymphoma

A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB(PRT062070) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL or T-CELL NON-HODGKIN LYMPHOMA

Lymphoma

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Lymphoma

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Lymphoma

A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma

Mantle Cell Lymphoma (MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Merkel Cell Carcinoma (MCC)

A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy

Merkel Cell Carcinoma (MCC)

Phase 2 Study of INCMGA00012 in Patients with Metastatic Merkel Cell Carcinoma (POD1UM-201)

Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

Metastatic Breast Cancer

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A,), AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS ADO-TRASTUZUMAB EMTANSINE (T-DM1) FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER S

Multiple Myeloma

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to Lenalidomide

Multiple Myeloma

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Pla

Multiple Myeloma

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma

Muscle Invasive Bladder Cancer (MIBC)

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Mus

Myeloproliferative Neoplasms

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)

Non-Hodgkin’s Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Small Cell Lung Cancer (NSCLC)

A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with PD-L1+ Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)

Non-Small Cell Lung Cancer (NSCLC)

An open-label Phase I dose finding trial with BI 891065 alone and in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in patients with advanced and/or metastatic malignancies

Non-Small Cell Lung Cancer (NSCLC)

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inh

Oral Mucositis

ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer

Oropharyngeal Cancer

NRG-HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Ovarian Cancer

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer

A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Pancreatic Adenocarcinoma

PANOVA 3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for frontline treatment of locally-advanced pancreatic adenocarcinoma

PEComa – Perivascular epithelioid cell neoplasms

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Metastatic Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Releva

Peripheral T-Cell Lymphoma (PTCL)

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Prostate Cancer

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-resistant Prostate Cancer and DNA-Repair Anomalies

Prostate Cancer

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer

Prostate Cancer

A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer

Sickle Cell Disease (SCD)

HbO2 Hemopure – HBOC-201 (IND# 18513)

Small Cell Carcinoma

REPLATINUM: A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Solid Tumors

A randomized, open-label, multicenter, phase 1b/2 trial evaluating the safety and efficacy of intratumorally-administered ilixadencel in combination with checkpoint inhibitor (CPI) in advanced cancer patients who are candidates for CPI therapy

Solid Tumors

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Solid Tumors

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072)

Squamous Cell Carcinoma

A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)

T-Cell Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

Triple Negative Breast Cancer (TNBC)

A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Ce

Warm Autoimmune Hemolytic Anemia (wAIHA)

A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

How to make colonoscopy prep easier

Colonoscopy prep is nothing to dread. Think of it as a good cleaning out with none of the pain or ill feelings you may associate with diarrhea. Planning ahead will make your colonoscopy prep easier. […]

Read Full Story

African Americans at higher risk for colorectal cancers, but screenings lag

According to the American College of Gastroenterology, African Americans have the highest rate of death and the shortest rate of survival for colorectal cancer. In fact, African Americans are 45% more likely than other groups […]

Read Full Story

Back from stage 3 ovarian cancer, Stephanie Virgin is a mom and thriving professional

Photo by Anna May Photography Stephanie Virgin was 29 and hoping to start a family, so ovarian cancer was the last thing on her mind — even when she experienced textbook symptoms. The Louisville native […]

Read Full Story

Surgeon’s mission trip takes expertise in women’s surgery to Nicaragua

Each year, more than 200 women are able to see David L. Doering, M.D., for issues requiring surgery for gynecologic cancers. A “Master Surgeon” as designated by the Surgical Review Corp., Dr. Doering uses minimally […]

Read Full Story

Lung screening catches woman’s cancer, avoids need for chemo or radiation

Margaret Taylor, 72, started smoking as a 14-year-old growing up in Tell City, Indiana. It became an addiction of at least a pack a day that lasted a total of 46 years. “Things were different […]

Read Full Story
Related Stories

How to make colonoscopy prep easier

Colonoscopy prep is nothing to dread. Think of it as a good cleaning out with none of the pain or ill feelings you may associate with diarrhea. Planning ahead will make your colonoscopy prep easier. […]

Read Full Story

African Americans at higher risk for colorectal cancers, but screenings lag

According to the American College of Gastroenterology, African Americans have the highest rate of death and the shortest rate of survival for colorectal cancer. In fact, African Americans are 45% more likely than other groups […]

Read Full Story

Back from stage 3 ovarian cancer, Stephanie Virgin is a mom and thriving professional

Photo by Anna May Photography Stephanie Virgin was 29 and hoping to start a family, so ovarian cancer was the last thing on her mind — even when she experienced textbook symptoms. The Louisville native […]

Read Full Story

Surgeon’s mission trip takes expertise in women’s surgery to Nicaragua

Each year, more than 200 women are able to see David L. Doering, M.D., for issues requiring surgery for gynecologic cancers. A “Master Surgeon” as designated by the Surgical Review Corp., Dr. Doering uses minimally […]

Read Full Story

Lung screening catches woman’s cancer, avoids need for chemo or radiation

Margaret Taylor, 72, started smoking as a 14-year-old growing up in Tell City, Indiana. It became an addiction of at least a pack a day that lasted a total of 46 years. “Things were different […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.